CM-082

Summary

Cm-082 (CHEMBL3545427) is a phase-3 clinical-stage unknown; indicated across 7 conditions including renal cell carcinoma and age-related macular degeneration.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 7 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545427
Name	CM-082
Type	Unknown
Max phase	3

Also known as: Cm-082, CM-082

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
renal cell carcinoma	3	MONDO:0005086	EFO:0000681
age-related macular degeneration	2	MONDO:0005150	EFO:0001365
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
neoplasm	1	MONDO:0005070	EFO:0000616
gastric neoplasm	1	MONDO:0021085	MONDO:0001056

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).